Comprehensive pathological assessment of histological subtypes, molecular subtypes based on immunohistochemistry, and tumor‐associated immune cell status in muscle‐invasive bladder cancer. Issue 3 (27th January 2021) - Ikeda, Junichi
Abstract : Molecular assessments of muscle‐invasive bladder cancer (MIBC) have yielded several molecular categorizations associated with basal and luminal subtypes or tumor‐associated immune cell status (TAICs). However, the histological relationships among histological subtypes, molecular subtypes, and TAICs and their clinical implications remain unclear. Thus, we aimed to evaluate the histological associations among these factors and their clinicopathological outcomes. We retrospectively analyzed 106 patients with MIBC who underwent radical cystectomy. The histological subtypes and TAICs were evaluated with hematoxylin and eosin staining, while the basal and luminal molecular subtypes were determined by immunohistochemical expression of cytokeratin (CK) 5/6, CK14, CK20, GATA3 and uroplakin II. Urothelial carcinoma with squamous differentiation and the sarcomatoid variant were highly associated with the basal subtype ( P < 0.001 and P = 0.04, respectively). Additionally, high TAICs were significantly correlated with the basal subtype ( P < 0.001). Although there was no significant difference in the cancer‐specific survival (CSS) rate between molecular subtypes ( P = 0.295), TAICs significantly discriminated CSS rates ( P < 0.001). Furthermore, the combination of molecular subtypes and TAICs significantly stratified cancer‐specific mortality rates. In conclusion, a comprehensive pathological evaluation of histological subtypes, molecular subtypes, and TAICs is feasible and can influence the oncological outcome.